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The only product changes in the pharmaceutical industry 
until the early 1960s were the development of new and more 
sophist1cated medications. It was in the early 1950s that 
gener1c drugs were introduced, but the early 1960s showed a 
g1•eat 1ncrease in the number of generic drugs in the 
marketplace. Many people did not know then what actually 
made a generic drug different from a brand name drug, but 
they did know that there was a cost savings of the gener1c 
drug over the brand name drug (Carroll, 1986). 
Most brand name drugs have been 1n existence for a 
number of years and have been regulated by the government. 
Regulation concerning generic drug substitution was not 
started until 1961 when formal statutes, both federal and 
state were enacted (Hamm, 1980). A generic drug could be 
developed from a prescription drug when the patent had run 
out on the drug. The time limit for a patent exp1ration on a 
prescript1on drug is 17 years. Once that time has passed, a 
generic substitute can then be presented to the American 
Medical Association (AMA) listing its chemical make-up and a 
suggested generic name for approval. Once the AMA has given 
its approval, the drug is checked by the United States Food 
and Drug Administration (FDA) to determine its safety and 
effectiveness. Since a generic drug is often viewed as a 
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copycat of a brand name drug, it has been spared much of the 
testing involved with a completely new drug on the market. 
Generic drugs have been making gains in the 
pharmaceutical industry. It is currently estimated that 15% 
to 20% of all prescription drugs have generic substitutes 
(Lavrakas, 1986). In 1978, an FDA report showed that 70 of 
the most frequently prescribed drugs were available as a 
generic product (Hamm, 1980). In November of 1985, the FDA 
approved 169 new generic versions for release in the 
marketplace (LavrakasJ. In a further report by the FDA, 1t 
was estimated that by 1990, the top 50 drugs on the market 
would have generic substitutes (Lavrakas). 
As with most medical issues, the subJect of generic 
drug substitution is complicated. It has created mixed 
signals caused from differences 1n government reports and 
medical literature from physic1ans, pharmacists, and 
consumers who are familiar with generic drugs (Schwartz, 
1985). A rul1ng by the FDA in 1984, reduced the required 
testing a company would have to do before marketing a new 
generic drug product. It will create more problems due to 
the number of drugs that the FDA will have to approve as 
patents on older drugs continue to expire and generic drugs 
are produced. 
The controversy regarding generic drugs has developed 
from a variety of sources. A statement from the Academy of 
Pharmaceutical Sciences of the American Pharmaceutical 
Association (APA), said · Drug products from different 
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sources may differ in quality in several respects. These 
differences, individually or collectively, may lead to 
substantial differences in therapeutic effect and/or safety" 
( 1 9 7 0 , p . 1 0 9 ) . They went on to s a y , · d i f f ere n c e s i n the 
rate and completeness of release of the active ingredient 
may result in varying therapeutic or adverse effects. This 
is true of a variety of products whose number is still 
uncertain, but potent1ally large" (p. 109). The APA was 
taking the first step to identify a quality and 
effectiveness problem of generic drugs. 
In 1974, Congress dec1ded to 1mplement a generic 
substitution program with the goal of saving on health care 
costs, but wanted to examine the possibility of patient 
medical problems from such a move. It gathered a group of 
outstanding scientists and physicians to assess the 
scientific issues of generic drugs. The Congressional Office 
of Technology Assessment COTA) hosted the conference and had 
scientists and physicians focus on drug bioequivalence. 
Additionally, the scientists and physicians were to 
determine whether to endorse the concept of generic 
substitution. The conference did endorse gener1c drug 
substitution, however, the endorsement also warned 
physicians and pharmacists to exercise caution in 
prescribing generic drugs due to the lack of bioequivalence, 
having the same chemical combining capabilities. The OTA 
report concluded: 
Current standards and regulatory pract1ces do not 
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insure bioequivalence for drug products. Variations in 
the bioavailability of drug products have been 
recognized as responsible for a few therapeutic 
failures. It iS probable that other therapeutic 
failures (or toxicity) of a similar origin have escaped 
recognition (1974, p. l). 
After the final OTA report was issued, Consumer 
Reports (1975) concluded, "the controversy over 
bioequ1valence has at last been put into perspect1ve. Ask 
your doc tor to prescribe a drug by its generic name.. ( p. 
51). Consumer Reports, which is more widely c1rculated to 
the general public than the government reports was informing 
consumers that there were no problems w1th generic drugs 
and that to make sure you got the correct generic drug, 
specify the drug on the prescription. It offered no warnings 
to the consumer. The FDA wanted to end the controversy by 
publishing a report in a 1978 issue of the Food and Drug 
Administration Consumer, stat1ng: 
All drugs, whether they are sold under their brand 
names or generic names, must meet the same Food and 
Drug Administration standards for safety, strength, 
purity, and effectiveness. And all manufacturers, big 
or small, are subject to Food and Drug Adm1nistrat1on 
inspection and must follow the agency's current good 
manufacturing practice regulations. That is why the 
Food and Drug Administration believes that there is no 
sign1ficant difference between generic and brand name 
drugs (Hecht, 1978, p. 1). 
The debate continued in 1981 in an address by the 
deputy director of the Division of Biopharmaceuticals of 
the Food and Drug Administration, J. Skelly (1981), 
indicated "perhaps somewhat surpr1sing that only 45 
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percent of the total manufactured prescription drug products 
in the marketplace two years ago have been approved for both 
safety and efficacy." This debate quest1oned whether a 
product that was interchangeable with a brand-name product 
was ever really considered safe. 
The controversy over generic drugs continues today. 
With the growth of generic drugs in the marketplace and the 
enticement of dollar savings to the consumer, the consumer 
should become more familiar w1th generic drugs and the 
substitution policy affecting these drugs. 
The problem presented by this study 1s that there is a 
lack of information available on generic drugs and that 
consumers do not know all they should about generic drug 
substitution. With the increase of generic drugs available 
for doctors to prescribe and for pharmacists to dispense and 
substitute, the consumer must be kept aware of what exactly 
he or she is receiving. The consumer should be concerned 
about federal and state gener1c drug substitution policies 
that affect the prescribed drug the consumer receives. With 
the use of a generic drug, a consumer should then know what 
difference the drug may have in its prescribed performance 
effects as compared to a brand name drug. 
The purpose of this study was to investigate the 
scientific considerations of prescribing and taking gener1c 
drugs and to learn about the federal and state laws that 
govern generic drug substitution. 
Definitions 
Bioavailabllity - percentage of the active ingredient that 
is released 1n the body taking into account patient 
characteristics, formulation of the drug product and 
the co-administration of other drugs. 
Bioequivalence - having the same chemical combining 
capabilities as a generic drug compared to its brand 
name equivalent. 
Bioinequivalence - not having the same chemical comb1n1ng 
capabilities. 
Brand name - a class of goods identified by name as the 
product of a single fi~m or manufacturer. 
Clinical equivalence - a restricted range of variation in 
bioavailability relative to the norm set by the 
innovator product. 
Generic - common to or characteristic of a whole group or 
class. 
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REVIEW OF LITERATURE J 
Scientific Considerations 
The debate regarding generic substitution of drug 
products is centered around three factors, that of the 
generic product's quality, its interchangeability with the 
product prescribed, and the cost of the alternat1ve product. 
In looking at the scientific issues of generic drug 
substitut1on, the areas of quality and interchangeab1lity 
will be discussed. 
The FDA guidelines have ma1nta1ned the general rule 
concerning gener1c drugs that "drug products will be 
cons1dered therapeutically equivalent except where the 
agency be 1 i eves that bioi nequi valence exists· (Knapp, 1979, 
p. 99). In studying these FDA guidel1nes, Leroy Schwartz, 
M.D., once head of the FDA, stated "The Food and Drug 
Administration has decided that certain generic 
pharmaceutical products can be deemed clinically equivalent 
to the innovator product though they have been declared 
bioinequivalent" (1985, p. 41). The emphasis became the 
difference between clinical equivalence and bioequivalence 
which have different medical connotations. The FDA actually 
has a restricted range of variation in bioavailability 
relative to the brand name product for which the generic 
drug was derived. The guidelines further stated by Leroy 
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Schwartz and Culkin (1983) of the FDA are: 
In general, the variability in bioavailability between 
generics and the reference product, measured as the 
difference in mean areas under the curve CAUCs), is 
allowed to extend up to 20 percent for the gener1c 
product to be considered clinically equivalent. 
However, for certain drugs (e.g., trifluoperazines) a 
30% allowance is granted, whereas for other drugs (e.g., 
warfarins) only a 10 difference in mean AUC is 
permitted. 
In examining these guidelines stated by the FDA, it was 
determined that there was no clinical basis to arrive at 
these standards (Schwartz, 1985). One study determined that 
the p~rcent allowances used were arbitrary and also cited 
studies from Canada to show that the difference in 
bioavailability was undetectable (Schwartz, and Culk1n, 
1983). The FDA also stated that because there were no 
significant complaints of therapeutic failure, that the 
percentage allowances caused no clinical problems. The main 
problem can be seen if a patient had one product with a 
bioavailability of 30% below the standard at one pharmacy, 
and a refill of the product with a bioavailability of 30% 
above the standard at another (Lamy, 1984). The patient 
would therefore have at most a 60% difference in the amount 
of the active ingredient absorbed from one product to the 
next (Lamy, 1984). 
The tests that were accomplished to measure 
bioavailability of certain products were done on young, 
healthy adults which indicates a problem of whether the 
generic drugs may be acceptable for the more sensitive 
patients as the elderly, infants, and children (Levy, 1985) 
With the large variance in bioavailability for the more 
frail patient, the question was raised: "Would a physician 
agree to prescribe a generically equivalent product for an 
elderly pat1ent if, indeed, equivalency may vary greatly?" 
(Lamy, 1984, p. 92). If a patient has been stabil1zed on a 
certain product, certainly a change to a generic equivalent 
should not be used. The possibility of an overdose is 
greater with a large percentage change from one drug to its 
generic equivalent. 
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The question of use of generic substitutions on infants 
and children in regard to bioavailability is greatly in 
question. The American Academy of Pediatrics stated that 
"few drug products have been appropriately studied for 
bioavailability in infants and children" (1976, p. 275) 
Studies of differences in a drug product's bioavailabil1ty 
may be greatly enlarged when considering 1nfants' and 
children's large differences in drug absorption, 
distribution, and excretion. 
Three areas where doctors have felt that generic 
substitution is not acceptable is that of psychotropic 
(mental) disorders, cardiovascular, and metabolic drugs. The 
Task Force on Bioavailability and Bioequivalence of the 
American College of Neuropsychopharmacology (1979) stated: 
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It would be most undesirable to use multi-source 
psychotropic drug products interchangeably without 
establishment of their bioequivalency. It is our belief 
that without such Federal requirements there may, in 
fact, be bioinequivalency among these psychotropic 
drugs occurring either now or in the near future due to 
the repeal of antisubstitution laws in over two thirds 
of the states in this country (p. 3). 
The Task Force continued to address problems of determining 
if a mental disorder could be properly treated if a drug 
could hinder or disguise a reliable report from a patient 
since a substituted drug may not perform as well on the 
patient as the brand-name drug would. 
The scientific issues are weighed against generic drugs 
in looking at the quality and interchangeability of brand-
name drugs to generic drugs. It is indicated that further 
research and testing be accomplished on generic drugs to 
ensure their bioavailability as compared to brand name 
drugs. 
Federal Laws Concerning Generic 
Drug Substitution 
Generic drugs have existed since early prescription 
drug days, but were not regulated until 1961 when the 
regulation of generic drugs came 1n the form of federal and 
state laws which allowed substitution of generic drugs for 
brand name drugs. Before these laws were passed, brand name 
drugs could not be substituted with generic drugs. As part 
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of the 1961 laws, the federal government approved that a 
pharmacist could substitute a generic drug for a brand name 
drug w1th the permission of the prescriber or buyer. This 
statute started the development of a market of generic drugs 
which has grown ever since. 
Since the 1961 statute allowing generic drug 
substitution, the federal government has made little change 
in its regulation of generic drugs (Hamm, 1980). The 
federal agency that has the final approving authority of any 
drug including generic drugs is the Food and Drug 
Administration (FDA). For approval of a drug, it must be 
proven to be both safe and effective. The term "safe" is 
relative, as no drug is totally safe for all people, and a 
physician must decide whether the benefits of a specific 
drug outweigh the dangers it may pose to the patient. 
Before a new drug can enter the market, scientific studies 
must be accomplished, first on animals, then on humans. 
Through these studies, it is determined whether the drug 1s 
safe and effective for general use. The FDA oversees much of 
the scientific research on drugs and once a manufacturer 
bel1eves a drug is both safe and effective, it asks the FDA 
if the drug can be marketed. The FDA usually reviews the 
results of the research and decides if the drug can be 
placed in general use or whether more study is needed. 
Generic drug testing is quite different from 
introducing a brand name product to the market. In the 1960s 
when generic drugs were becoming more common, and generic 
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drug substitution was increasing, the FDA was demanding the 
same tests for generic drugs as were required for new brand 
name drugs. Since the number of generic drugs were 
increasing with the deregulation of their use and the 
consumer demanding the lower priced drugs, the FDA was over 
tasked to approve the drugs. Eventually, the FDA gave in and 
eliminated much of the testing required for approval of a 
generic drug into the marketplace. 
In September of 1984, Congress passed a step to 
decrease the time that the FDA had to process and approve a 
generic drug (Lavrakas, 1986). This was called the Drug 
Price Competition and Patent Term Restoration Act. It was 
passed mainly due to concerns about getting generic 
substitutes into the marketplace to consumers, namely 
government benefit recipients, a savings on prescription 
drugs. It mandated the FDA to process and approve new 
generic drug applications within 180 days. It greatly 
simplified the procedures for generic drug approval. 
New procedures which the FDA developed, required a 
manufacturer to do certain things before granting approval 
of a generic drug (Lavrakas, 1986). The FDA told the 
manufacturer that instead of the lengthy clinical tests it 
normally would run, it would require the manufacturer to 
prove that the product was therapeutically equivalent to a 
brand name product. The FDA then stated that it would 
approve a generic drug for public sale if it met the 
following criteria: 
1. Used the same active ingredients. 
2. Have identical dosage strength. 
3. Be of the same dosage form (tablet, solution) 
4. Be administered by the same route (mouth, 
injection). 
5. Be used for the same illness. 
5. Is bioequivalent (destination in the body in 
the same amount and time). 
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Once these items were proven to the FDA, a test on 20 to 30 
normal patients would be tried. In comparison, a new drug 
must be tested on at least 40 times more patients wh1ch is a 
better sampling to ensure the safety of the drug. This 
simplified process is the current approval process for a 
generic drug. 
With the new approval process enacted, the Head of the 
Food and Drug Administration's Division of Generic Drugs, 
Dr. Marvin Seife, stated "These [brand name and generic 
drugs] are interchangeable; they are mirror images of each 
other" (Lavrakas, p. 12). Shortly thereafter, several 
pharmaceutical manufacturers asked for more extensive tests 
on generic drug versions due to concerns they had on the 
safety of some generic drugs. The FDA responded by saying 
that the concerns were "scientifically groundless." 
The FDA continued to be put to the test in approving 
new generic drugs, and in November of 1985, set a record of 
approving 169 new generic versions. At the same time, it had 
500 Abbreviated New Drug Applications (ANDA) pending 
approval. It was estimated that by 1990, the top 50 drugs 
would have generics (Lavrakas, 1986). 
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The federal government has made few changes to the 
statutes governing generic drug substitution, but by 
deregulating substitution, manufacturers have found a larger 
market to exploit. The FDA has an enormous responsibility in 
approving both brand name and generic drugs for public use. 
Its changed approach to approving generic drugs has been 
questioned by even the manufacturers themselves and should 
be questioned by the government and consumer also. The 
market for generic drugs will continue to grow and challenge 
the government for effective regulations concerning their 
safety and control. 
Oklahoma Laws On Generic 
Drug Substitution 
State regulation of generic drug substitution started 
with the enactment of federal legislation allowing generic 
drug substitution in 1961. The current regulation on 
pharmacy practice is called the Oklahoma State Laws 
Pertaining to the Practice of Pharmacy, dated 1972, and 
published by the Oklahoma State Board of Pharmacy. Some 
revisions have been made in the laws concerning 
pharmaceutical practice, but the area of generic drug 
substitution has not been changed since 1961. 
The Oklahoma state laws governing the practice of 
pharmacy in the state include a section specifically for 
generic drug substitution. The Oklahoma State law pertaining 
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to generic drugs, states: 
It shall be unlawful for any pharmacist being requested 
to sell, furnish or compound any drug, medicine, 
chemical or other pharmaceutical preparation, by 
prescription or otherwise, to subst1tute or cause to be 
substituted therefore, without authority of the 
prescriber or purchaser, any other drug, medic1ne 
chemical or pharmaceutical preparation (Oklahoma State 
Board o f Pharmacy , 1 9 7 2 , p . 1 5 ) . 
Very simply, what is needed for a pharmac1st to subst1tute a 
generic drug is the approval of the prescriber or the 
purchaser. The prescriber, namely the physician, knows what 
a person should need in the way of a specific prescription 
drug and may imprint on the prescription form that the 
pharmac1st must dispense the drug as written. The physician 
may also note on the prescr1ption form that a substitute 
drug may be given. If the physician does not state the 
restrictions, the pharmacist has an option of substituting a 
generic drug for the brand name drug prescribed. In this 
case, the consumer's approval is required before the 
substitution can be made. The problem then is whether a 
consumer really knows about the substituted drug's safety 
and effectiveness. 
Many pharmacists are willing to substitute generic 
drugs for brand name drugs, mainly to save the customer some 
expense. Pharmacists advertise their use in newspapers, the 
Yellow Pages, and most often in their own stores. Typical 
signs include: 
Money Saving Generic Drugs 
Are Available 
For Some Prescriptions 
or 
Ask Your Pharmacist If 
There Is A Generic Drug 
Available For Your Prescription 
By state law, a pharmacist is required to have 
reference books on pharmaceutical products. They include a 
recent copy of the Oklahoma State Laws Pertaining to the 
Practice of Pharmacy and a Blue Book or Red Book which are 
books contain1ng tables of drugs which state a drug's 
properties, recommended dosages, and the standards wh1ch 
determine their strength and purity (Oklahoma State Board of 
Pharmacy, 1972, p. 16). Optional reference books include 
combinations of a modern drug encyclopedia, USP N. F. Mercks 
(a drug manufacturer and referencing drug agent), USD 
Remington-Emergency Toxicology (a reference for toxic or 
poisonous drugs), and a medical dictionary on pharmacy 
compounding and dispensing book. Brand name and generic name 
drugs are listed in some or all of the references and are 
cross-referenced for brand names and generic names. 
Since the laws offer no guidance in consumer 
understanding of specific drugs and only stste the approval 
required for a generic drug substitute, consumers should be 
sure to know their rights pertaining to the policies of 
16 
17 
generic drug substitution. In doing so, a consumer may ask a 
pharmacist relevant questions pertaining to a specific 
generic drug's safety and effectiveness. 
Concerns Regarding The Future 
Of Prescribing 
With the continued rise in health care costs, there 
will be increased emphasis on the use of generic substitutes 
whenever possible. Some states may eventually require 
substitution and doctors who prescribe a brand name drug to 
be used, may have to state "medically required" so that a 
substitute is not given (Schwartz, 1985). A term that is 
becoming more common when discussing generic drug 
substitution is that of therapeutic substitution. This 
implies that a subst1tuted drug would have to have the same 
general pharmac~logic and therapeutic class in combination 
to that of the drug prescribed. This would broaden the 
categories of substitute drugs available to be prescribed 
for specific treatments. The pharmacist would then give the 
patient whatever product that would correct the problem from 
the therapeutic class of drugs. 
Another concern regarding the future of medical 
treatment involves the pharmacist prescribing medication for 
primary care. The patient would see a pharmacist for a 
primary care diagnosis and have a prescription ordered as a 
remedy. If it was more serious, obviously a physician would 
have to become involved. 
The concept of therapeutic substitution could be a 
reality. With the continued concern for generic 
substitution, Koch-Weber (1974) summed up generic 
substitution, warning: 
18 
Once the effective and safe dose of any one drug 
product has been established in a given patient, 
substitution of alternative products with markedly 
different bioavailability could be catastroph1c, 
particularly when it occurs w1thout the physician's 
knowledge. Under present circumstances, free 
substitution of another drug product of different 
bioavailability for that prescribed by the phys1cian 
could expose a patient to ser1ous risks of intoxicat1on 
due to greater absorption of the active drug or to 
therapeutic failure because of bioavailability (p. 
236) . 
It appears that generic substitution involves some questions 
and problems for physicians, pharmacists, and the consumer. 
We are faced with more serious problems that generic 
substitution now may be replaced with therapeutic 
substitution or prescribing by pharmacists. 
SUMMARY AND CONCLUSIONS 
Changes 1n the pharmaceutical industry have been great 
with the capability of developing new and improved 
prescription drugs. Generic drugs have been taking a greater 
share of the prescr1ption drug industry with the patent 
expiration on aging drugs .. With the increasing prescript1on 
and use of generic drugs, consumers should become more 
familiar with generic drugs and the substitution policy of 
these drugs. 
A key concern for today's consumer is to save money. 
This includes saving on medical expenses which have 
increased at alarm1ng rates. Generic drugs have offered 
consumers some savings, and these saving have been the key 
to the success of generic drugs. A cost savings is very 
important to consumers, but safety should remain the overall 
concern to the consumer of prescription drugs. Many 
consumers are not completely aware of the controversy 
surrounding their use and substitution. 
The scientific considerations of quality and 
interchangeability of a prescribed product indicate that not 
all generic drugs are bioequivalent to their brand name 
counterpart as defined by the FDA. The bioavailability of a 
generic drug can have a substantial deviation from its brand 
name drug which can ~ignificantly affect its therapeutic 
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affects. Identifying specific high risk groups that can be 
greatly affected by the deviation of bioavailability between 
a brand name and generic drug, indicate potential problems 
with established therapeutic effects as stated by the FDA. 
The federal and state laws which govern the 
substitution of gener1c drugs are centered around a cost 
savings for the consumer also. They do not consider 
testing that is required on a new drug about to enter the 
marketplace. Generic drugs are tested quite differently than 
a new brand name drug. The federal government has made few 
changes to the approval process of generic drugs and have 
continued in its simplified process of approval. State laws 
concerning generic drugs have not changed since created in 
1961, and lend little guidance to a consumer on generic drug 
substitution. 
Scientific considerations and current federal and state 
laws regarding generic drugs and the substitution of these 
drugs indicate that there are potential problems in the 
generic drug industry, some actions need to take place. The 
key issue of safety in the drug industry can not be ignored. 
The place to start is to better define the parameters for a 
generic drug to be considered bioequivalent to a brand name 
drug and thus eliminate any concerns of quality or 
interchangeability. Once these parameters are established, 
the FDA can then evaluate those drugs that do not meet 
specifications as stated, and then begin the testing of 
these products as they normally would if it was a new 
prescription drug entering the market. The FDA would have 
to uphold the standards through strict regulations. The 
problem that may occur and hold up this process is 
political. Pharmaceutical companies have strong lobbies 
which would have to be contended with while the new 
legislation of generic drug testing was started. Having to 
interrupt the multimillion dollar drug industry while new 
testing and evaluations on drugs were going on could cause 
problems. The issue to consider again however, is the 
individual consumer who deserves a safe and effective 
prescription drug. 
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An issue that the consumer can take upon individually 
is to get to know more about the drug industry, especially, 
the generic drug industry. Questioning your physician and 
pharmacist on the particular drugs prescribed is a start. 
Ask your medical professionals if they know about generic 
substitutes to your prescribed drug to see if it is as safe 
and effective as the brand name drug. If there are any 
questions on a generic drug, know the answers before 
accepting the generic substitute. 
With emphasis of saving money, it is important for 
consumers to buy wisely. In many cases, it is easy for a 
consumer to make the right decisions, but the purchasing of 
all products continues to get more complex every day. When 
it comes to health products, greater concern must be taken 
and the area of prescription drugs is where a good consumer 
must study and evaluate the options. Generic drugs are an 
answer to high priced brand name drugs, but considerations 
must be taken to ensure they are as safe and effective as 
their brand name counterparts. 
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